Fate Therapeutics Q4 2023 GAAP EPS $(0.45) Beats $(0.53) Estimate, Sales $1.68M Beat $1.59M Estimate
Author: Benzinga Newsdesk | February 26, 2024 05:09pm
Fate Therapeutics (NASDAQ:
FATE) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.53) by 15.09 percent. This is a 22.41 percent increase over losses of $(0.58) per share from the same period last year. The company reported quarterly sales of $1.68 million which beat the analyst consensus estimate of $1.59 million by 5.11 percent. This is a 96.22 percent decrease over sales of $44.36 million the same period last year.
Posted In: FATE